CSMS Message: 16-000830

Title:CBP/FDA Instructions for Filing FTZ Withdrawals (Entry Type 06 and 21)
Date:2016-09-20
To:abi,newace,partner
Links:previous, original, next

In accordance with FDA's Supplemental Guide 2.4.1, functionality was made available in ACE today, September 20, 2016, for electronic filing of Foreign Trade Zone (FTZ) withdrawals (entry type 06 and 21).

For FDA, Prior Notice is required for foods entering a FTZ, therefore, prior notice is not required when the goods are withdrawn from the zone. The following instructions provide details for filing FTZ withdrawals in ACE:

For Entry Type 06:
1. The FTZ FIRMS Code must be supplied to CBP in the SE11 (positions 12-15).
2. FDA line data should be filed as usual. No PN is required for Entry Type 06.

For Entry Type 21 (Withdrawal): Per FDA Supplemental Guide 2.4.1, if entry type is 21 and the goods are being withdrawn from a zone:
1. The filer provides FDA line information as usual (PN information is not required for FTZ withdrawals).
2. In addition to the required PG30 record with Anticipated Arrival Information date, time, and port, filers must transmit a second PG30 with an “F” in the “Inspection/Laboratory Testing Status” field to indicate FTZ withdrawal. The second PG30 applies to food or any other product that is being withdrawn from an FTZ (position 5).
3. In the second PG30, the filer must also provide a PG30 with “4” in the “Arrival / Entry Location Code” field (position 18).
4. In the second PG30, file must also provide a valid Firms Code Value in the “Port of Arrival / Entry” field (positions 22-25).
5. Arrival date and time are optional in the second PG30.

Note: Valid firms codes may be located at: https://www.cbp.gov/sites/default/files/assets/documents/2016-Sep/FIRMS30_0.TXT The report is updated every two weeks.

Failure to follow instructions may result in entry rejection.

Reference CBP's ACE CATAIR here: https://www.cbp.gov/trade/ace/catair
Reference FDA's Supplemental Guide 2.4.1 here: https://www.cbp.gov/document/guidance/fda-supplemental-guide-release-16

Questions about these requirements should be directed to ACE_Support@fda.hhs.gov